Pipeline
Latest progress of our drug discovery programs
Program
Target
Indication
Discovery
IND-Enabling
Phase 1
Targeted Protein Degradation
AC0682
ER Degrader
Breast Cancer
AC0176
AR Degrader
Prostate Cancer
Broad mutant coverage
AC0676
BTK WT & C481S
HemOnc & Autoimmune
High selectivity
Discovery
Undisclosed
Multiple Novel E3 Ligases
Undisclosed
First-in-Class
Small Molecule (Precision Oncology)
Discovery
Undisclosed
Lung Cancer
Discovery
Undisclosed
Solid Tumors
Workflow
Complete AI solution for preclinical drug discovery
Preclinical workflow
Accutar Biotech AI solution
Traditional approach
1
Target discovery
Accutar pan target cross-dock
Genetics and biochemistry phenotypic screen
2
Hit identification
High throughput screen or other screening formats
3
Hit validation
Hit validation by co-crystallization and binding assays
4
Lead identification
Lead optimization
Clinical lead selection
Medicinal chemistry optimization
Potency; absorption, distribution, metabolism, and excretion (ADME); and toxicology
5
Candidate nomination